New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

New Clinical Study Shows UC-II® is More than Twice as Effective as Glucosamine + Chondroitin

The results of a new clinical study on UC-II®, InterHealth Nutraceuticals’ patented, Type II collagen product were presented today at the American College of Nutrition. In a randomized, double-blind study of 52 patients, conducted in North America, one group took 40mg UC-II® and the other a combination of glucosamine (1500mg)+ chondroitin (1200mg). The results show that UC-II® showed a significant improvement from baseline on all WOMAC, VAS, and Lequesne measurements over the glucosamine + chondroitin combination.

The study, presented at the American College of Nutrition meeting in Arlington, VA on October 3, 2008 by Dr. Bagchi PhD., F.A.C.N. demonstrates the efficacy of UC-II® in an older arthritic population experiencing joint pain and stiffness in the knees from osteoarthritis. It was observed that both treatments reduced the WOMAC index score which measures the difficulty in physical function, stiffness and pain in the knee. However, treatment with UC-II® was found to be significantly more effective and reduced the WOMAC score by 33% compared to 14% in glucosamine plus chondroitin treated groups after 90 days. Similar results were obtained for VAS scores. Although both the treatments reduced the VAS score, UC-II® was found to be most effective with 40% decrease after 90 days of treatment compared to 15.4% in glucosamine plus chondroitin treated groups. The Lequesne’s functional index was used to determine the effect of different treatments on pain during daily activities. Treatment with UC-II® reduced Lequesne’s functional index score by 20.1% compared to 5.9 % in glucosamine plus chondroitin treated groups. Thus, the UC-II® treated group showed improvement in daily activities suggesting an improvement in quality of life.

“This research shows the power of InterHealth’s UC-II® product,” stated InterHealth CEO Paul Dijkstra. “ What is most significant is that UC-II® shows better efficacy with a smaller, once daily, 40mg dose than the larger 2700mg dose of the glucosamine + chondroitin combination. With such a small, once daily pill, there will be better compliance and better joint health for millions of people. Our hope is that major supplement companies will want to bring this ingredient to their consumers and promote its effectiveness over glucosamine and chondroitin in joint health. UC-II® can be a standalone product or be incorporated into existing joint health, or senior health products. ”

The independent study was conducted at KGK Synergize Inc. in Canada with funding from InterHealth Nutraceuticals Inc. The study results will be submitted for publication in the next few weeks. “We are very pleased with the results and will continue to pursue research to show the efficacious benefits of UC-II®,“ says Dr. Bagchi.

About InterHealth Nutraceuticals, Inc.
InterHealth Nutraceuticals researches, develops, markets and distributes specialty nutritional ingredients, which are sold worldwide to manufacturers of dietary supplements and nutraceutical food and beverage products. In addition to UC-II®, the company’s products include Super CitriMax®, ChromeMate®, OptiBerry®, Aller-7®, L-OptiZinc®, Protykin® and ZMA®. For more information about InterHealth and its products, call 1-800-783-4636 or 1-707-751-2800 (outside U.S.) or visit the website at

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.